These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 28983953

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres.
    Lakhwani S, Perera M, Fernández-Fuertes F, Ríos de Paz MA, Torres M, Raya JM, Hernández MT.
    Eur J Haematol; 2017 Oct; 99(4):372-377. PubMed ID: 28759125
    [Abstract] [Full Text] [Related]

  • 3. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults.
    Červinek L, Mayer J, Doubek M.
    Int J Hematol; 2015 Jul; 102(1):7-11. PubMed ID: 25833724
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenic purpura: meta-analysis.
    Tumaini Massaro J, Chen Y, Ke Z.
    Platelets; 2019 Jul; 30(7):828-835. PubMed ID: 30810479
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study.
    Mahévas M, Fain O, Ebbo M, Roudot-Thoraval F, Limal N, Khellaf M, Schleinitz N, Bierling P, Languille L, Godeau B, Michel M.
    Br J Haematol; 2014 Jun; 165(6):865-9. PubMed ID: 24725224
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study].
    Weber E, Moulis G, Mahévas M, Guy C, Lioger B, Durieu I, Hunault M, Ramanantsoa M, Royer B, Default A, Pérault-Pochat MC, Moachon L, Bernard N, Bardy G, Jonville-Bera AP, Geniaux H, Godeau B, Cathébras P.
    Rev Med Interne; 2017 Mar; 38(3):167-175. PubMed ID: 27793553
    [Abstract] [Full Text] [Related]

  • 11. Treatment characteristics, efficacy and safety of thrombopoietin analogues in routine management of primary immune thrombocytopenia.
    Mingot-Castellano ME, Caparrós IS, Fernández F, Perera-Alvarez MDM, Jimenez-Bárcenas R, Casaus García A, González-Silva M, Yera-Cobo M, Nieto-Hernandez MM, Rodríguez-Fernandez MJ, Díaz-Canales D.
    Blood Coagul Fibrinolysis; 2018 Jun; 29(4):374-380. PubMed ID: 29738335
    [Abstract] [Full Text] [Related]

  • 12. Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study.
    Cai X, Fu H, Zhao X, Lu J, Jiang Q, Chang Y, Huang X, Zhang X.
    Chin Med J (Engl); 2022 Oct 05; 135(19):2344-2350. PubMed ID: 36535011
    [Abstract] [Full Text] [Related]

  • 13. Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP).
    Kapur R, Aslam R, Speck ER, Rebetz JM, Semple JW.
    Platelets; 2020 Oct 05; 31(3):399-402. PubMed ID: 31146647
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Thrombopoietin receptor agonists in patients with persistent or chronic immune thrombocytopenia.
    Agnelli Giacchello J, Valeri F, Boccadoro M, Borchiellini A.
    Eur J Haematol; 2018 Mar 05; 100(3):304-307. PubMed ID: 29243329
    [Abstract] [Full Text] [Related]

  • 16. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ.
    Clin Ther; 2009 Sep 05; 31(9):1887-907. PubMed ID: 19843480
    [Abstract] [Full Text] [Related]

  • 17. Cytokine changes in response to TPO receptor agonist treatment in primary immune thrombocytopenia.
    Qu MM, Liu XN, Liu XG, Feng Q, Liu Y, Zhang X, Liu S, Zhang L, Li GS, Zhu YY, Lv MY, Peng J, Hou M.
    Cytokine; 2017 Apr 05; 92():110-117. PubMed ID: 28142109
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T, Harada Y, Matsubara E, Suzuki T, Oyama T, Kasai M, Uchida T, Ogura M.
    J Clin Pharm Ther; 2012 Dec 05; 37(6):729-32. PubMed ID: 22583038
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.